1. Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
- Author
-
McEvoy, Ashleigh, Warburton, Lydia, Al-Ogaili, Zeyad, Celliers, Leisl, Calapre, Lesley, Pereira, Michelle R., Khattak, Muhammad A., Meniawy, Tarek M., Millward, Michael, Ziman, Mel R., Dr, Gray, Elin S., McEvoy, Ashleigh, Warburton, Lydia, Al-Ogaili, Zeyad, Celliers, Leisl, Calapre, Lesley, Pereira, Michelle R., Khattak, Muhammad A., Meniawy, Tarek M., Millward, Michael, Ziman, Mel R., Dr, and Gray, Elin S.
- Abstract
Background: Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB). Methods: Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR). Results: CtDNA was detected in 23 of 32 patients. Overall, a significant correlation was observed between ctDNA levels and MTB (p
- Published
- 2018